Drug Trial Radar · NCT06188559
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Apr 10, 2024
Primary completion
Mar 18, 2026
Study completion Mar 18, 2026
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer (BC).
Conditions
- Breast Cancer
Interventions
BB-1701Drug
BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1, Dose Optimization: Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 35 months
- Part 1, Dose Optimization: Number of Participants With Clinically Significant Laboratory ValuesTime frame: Baseline up to 35 months
- Part 1, Dose Optimization: Number of Participants With Clinically Significant Vital Sign ValuesTime frame: Baseline up to 35 months
- Part 1, Dose Optimization: Number of Participants With Clinically Significant 12-lead ECGs ValuesTime frame: Baseline up to 35 months
- Part 1, Dose Optimization: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)Time frame: Baseline up to 35 months
- Part 1, Dose Optimization: Objective Response Rate (ORR)Time frame: From date of first dose of study drug until first documentation of CR or PR (up to 35 months)
- Part 2, Dose Expansion: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment per RECIST v1.1Time frame: From date of first dose of study drug until first documentation of CR or PR (up to 35 months)
Locations
49 sites in 4 countries. Site status is shown where the registry gives one.
Cancer and Blood Specialty Clinic
Los Alamitos, California
UCLA Center for East-West Medicine
Los Angeles, California
UCSF
San Francisco, California
Yale New Haven Hospital
New Haven, Connecticut
AdventHealth Cancer Institute - Orlando
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Fort Wayne Medical Oncology & Hematology
Fort Wayne, Indiana
Community Cancer Center South
Indianapolis, Indiana
Mission Blood and Cancer
Des Moines, Iowa
University of Michigan Hospital
Ann Arbor, Michigan
Washington University in St. Louis School of Medicine
St Louis, Missouri
NHO Revive Research Institute LLC
Lincoln, Nebraska
Nebraska Cancer Specialist
Omaha, Nebraska
Astera Cancer Care
East Brunswick, New Jersey
Summit Medical Group
Florham Park, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico
Memorial Sloan-Kettering Cancer Center
New York, New York
Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center)
Cleveland, Ohio
Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Oregon Oncology Specialists
Salem, Oregon
UPMC CancerCenter at Magee - Womens Hospital
Pittsburgh, Pennsylvania
St. Francis Cancer Center
Greenville, South Carolina
Avera Cancer Institute
Sioux Falls, South Dakota
The West Clinic, PLLC dba West Cancer Cente
Germantown, Tennessee
Northwest Medical Specialties
Puyallup, Washington
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
Institut Régional du Cancer de Montpellier
Montpellier, France
Centre Armoricain de Radiotherapie Imagerie & Oncologie (CARIO)
Plérin, France
Institut de Cancerologie de Ouest (ICO) - Saint-Herblain
Saint-Herblain, France
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, Hiroshima, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Hyogo Medical University Hospital
Nishinomiya-shi, Hyōgo, Japan
Sagara Hospital, Social Medical Corporation Hakuaikai
Kagoshima, Kagoshima-ken, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Kyoto University Hospital
Sakyo-ku, Kyoto, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Okayama University Hospital
Okayama, Okayama-ken, Japan
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.